Pay in 4 interest-free payments of $7.02 Learn more
Ships within 48 hours · Estimated delivery Aug 9 - Aug 14
Where they overlap and where they don't Complementary Mechanism Targets Target Origin BPC-157 Gastric juice protein fragment (15 amino acids) TB-500 Thymosin Beta-4 fragment (LKKTETQ region) Target Primary action BPC-157 Local tissue repair signaling TB-500 Systemic cell migration and mobilization Target Angiogenesis BPC-157 VEGF upregulation, NO pathway TB-500 Endothelial migration, VEGF crosstalk Target Cell migration BPC-157 Indirect, via growth factors TB-500 Direct (G-actin sequestering) Target Best-evidence tissue BPC-157 Tendon, gut, gastric mucosa (preclinical) TB-500 Cardiac, corneal, skin (preclinical + early human T4) Target Reported in vivo half-life BPC-157 ~4 hours (animal estimates) TB-500 ~23 days (animal estimates) Half-life figures are pharmacokinetic estimates from animal studies
There has been limited research examining the efficacy of BPC-157 in humans, and the peptide has yet to receive formal approval for any therapeutic use
Key Takeaways Glutathione is a tripeptide antioxidant produced endogenously from glutamate, cysteine, and glycine, with cysteine availability being the rate-limiting factor in synthesis
Proper technique reduces risks like vein irritation, infection, or incorrect dosing
Once all the water is in, remove the syringe
Oral BPC-157 is often discussed for gastrointestinal concerns because it passes through the digestive tract and appears relatively stable in acidic environments
